Skip to main content
Journal cover image

Successful desensitization to oxaliplatin.

Publication ,  Journal Article
Mis, L; Fernando, NH; Hurwitz, HI; Morse, MA
Published in: Ann Pharmacother
May 2005

OBJECTIVE: To report the successful desensitization of a patient to oxaliplatin utilizing an 8-hour desensitization regimen in a controlled environment. CASE SUMMARY: A 53-year-old white woman with metastatic colon cancer was receiving oxaliplatin, bevacizumab, and capecitabine every 2 weeks, with a partial response to therapy. On her fifth cycle of this regimen, she experienced diaphoresis, hypotension, nausea, abdominal cramping, and coryza. According to the Naranjo probability scale, oxaliplatin, and not bevacizumab, was the probable cause of the hypersensitivity reaction. The woman continued therapy with capecitabine and bevacizumab, resulting in stable disease. Due to her initial response to the oxaliplatin-based regimen, it was decided to attempt desensitization to oxaliplatin in a controlled, inpatient environment. An 8-hour desensitization schedule was employed, and the patient successfully completed an additional 3 cycles with full-dose oxaliplatin. DISCUSSION: Hypersensitivity reactions to platinum-containing compounds are well described and potentially life threatening. With expanded use of oxaliplatin in various malignancies, an increased number of hypersensitivity reactions will likely be reported. Patients with previous hypersensitivity reactions to carboplatin are at risk for similar reactions to oxaliplatin. We achieved successful desensitization for oxaliplatin using increased concentrations of the drug over an 8-hour period concomitant with oral and intravenous corticosteroids and histamine blockers. CONCLUSIONS: Hypersensitivity reactions to platinum compounds may result in discontinuation of active therapies in patients with metastatic disease. Desensitization to oxaliplatin is possible utilizing this approach.

Duke Scholars

Published In

Ann Pharmacother

DOI

ISSN

1060-0280

Publication Date

May 2005

Volume

39

Issue

5

Start / End Page

966 / 969

Location

United States

Related Subject Headings

  • Pharmacology & Pharmacy
  • Oxaliplatin
  • Organoplatinum Compounds
  • Middle Aged
  • Humans
  • Female
  • Drug Hypersensitivity
  • Desensitization, Immunologic
  • Colonic Neoplasms
  • Antineoplastic Agents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mis, L., Fernando, N. H., Hurwitz, H. I., & Morse, M. A. (2005). Successful desensitization to oxaliplatin. Ann Pharmacother, 39(5), 966–969. https://doi.org/10.1345/aph.1E532
Mis, Lydia, Nishan H. Fernando, Hurbert I. Hurwitz, and Michael A. Morse. “Successful desensitization to oxaliplatin.Ann Pharmacother 39, no. 5 (May 2005): 966–69. https://doi.org/10.1345/aph.1E532.
Mis L, Fernando NH, Hurwitz HI, Morse MA. Successful desensitization to oxaliplatin. Ann Pharmacother. 2005 May;39(5):966–9.
Mis, Lydia, et al. “Successful desensitization to oxaliplatin.Ann Pharmacother, vol. 39, no. 5, May 2005, pp. 966–69. Pubmed, doi:10.1345/aph.1E532.
Mis L, Fernando NH, Hurwitz HI, Morse MA. Successful desensitization to oxaliplatin. Ann Pharmacother. 2005 May;39(5):966–969.
Journal cover image

Published In

Ann Pharmacother

DOI

ISSN

1060-0280

Publication Date

May 2005

Volume

39

Issue

5

Start / End Page

966 / 969

Location

United States

Related Subject Headings

  • Pharmacology & Pharmacy
  • Oxaliplatin
  • Organoplatinum Compounds
  • Middle Aged
  • Humans
  • Female
  • Drug Hypersensitivity
  • Desensitization, Immunologic
  • Colonic Neoplasms
  • Antineoplastic Agents